Policy Perspectives on Biomarker Testing Coverage for 2024

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries. 

“There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW

Hilary Gee Goeckner, MSW

Director, State and Local Campaigns, Access to Care

American Cancer Society Cancer Action Network

Washington, D.C.

This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences.

Resources:

The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions 

Comprehensive Cancer Care: The Role of Biomarker Testing 

Biomarker Testing for Medicaid Beneficiaries (Podcast) 

Access to Biomarker Testing - American Cancer Society Cancer Action Network  

The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog 

Improving Access to Biomarker Testing in Medicaid Populations 

Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog 

Patient Perceptions of Biomarker Testing – Oncology Issues 

Cancer Diagnostics - Biomarkers 

Eliminating Precision Medicine Disparities